Comparison of daunomycin effects on human keratinocytes and melanoma HTB 1410 cells. Image cytometry study

Anticancer Research

Volumn 23, Issue 1 A, 2003, Pages 419-426

  Drukala, Justyna ^a   Rajwa, Bartlomiej ^a,b   Pietrzkowski, Zbigniew ^c   Korohoda, Wlodzimierz ^a  

^a JAGIELLONIAN UNIVERSITY   (Poland)

^b PURDUE UNIVERSITY   (United States)

^c FutureCeuticals Inc   (United States)

Author keywords

Apoptosis; Daunomycin (daunorubicin); Human melanoma cells; Image cytometry; Keratinocytes

Indexed keywords

CELL DNA; DAUNORUBICIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL ACTIVITY; CELL COMMUNICATION; CELL GROWTH; CELL INTERACTION; CELL STRUCTURE; CONTROLLED STUDY; CULTURE MEDIUM; CYTOSTASIS; DNA DETERMINATION; DRUG ACTIVITY; DRUG EFFECT; DRUG SENSITIVITY; ENDOCYTOSIS; HUMAN; HUMAN CELL; IMAGE CYTOMETRY; KERATINOCYTE; MELANOCYTE; MELANOMA CELL; NICK END LABELING; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ACTINS; ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; CELL DIVISION; CELLS, CULTURED; CYTOSKELETON; DAUNORUBICIN; DNA; DNA, NEOPLASM; ENDOCYTOSIS; HUMANS; KERATINOCYTES; MELANOMA; MICROTUBULES; TUMOR CELLS, CULTURED;

EID: 0037234212     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Li G and Herlyn M: Dynamics of intercellular communication during melanoma evelopment. Mol Med Today 6: 163-169, 2000.
2. Breslow A: The surgical treatment of stage I cutaneous melanoma. Cancer Treat Rev 5: 195-198, 1978.
3. Buzzell RA and Zitelli JA: Favorable prognostic factors in recurrent and metastatic melanoma. J Am Acad Dermatol 34: 800-803, 1996.
4. Mannervik B, Castro VM, Danielson UH, Tahir MK, Hansson J and Ringborg U: Expression of class Pi glutathione transferase in human malignant melanoma cells. Carcinogenesis 8: 1929-1932, 1987.
5. Moral A, Palou J, Lafuente A, Molina R, Piulachs J, Castel T and Trias M: Immunohistochemical study of alpha, mu and pi class glutathione S transferase expression in malignant melanoma. Br J Dermatol 136: 345-350, 1997.
6. Campain A, Slovak ML, Schoenlein PV, Popescu NC, Gottesman MM and Pastan I: Acquisition of multiple copies of a mutant topoisomerase II alpha allele by chromosome 17 aneuploidy is associated with etoposide resistance in human melanoma cell lines. Somat Cell Mol Genet 21: 451-471, 1995.
7. Lage H, Jordan A, Scholz R and Dietel M: Thermosensitivity of multidrug-resistant human gastric and pancreatic carcinoma cells. Int J Hyperthermia 16: 291-303, 2000.
8. Runger TM, Emmert S, Schadendorf D, Diem C, Epe B and Hellfritsch D: Alterations of DNA repair in melanoma cell lines resistant to cisplatin, fotemustine, or etoposide. J Invest Dermatol 114: 34-39, 2000.
9. Jansen B, Inoue SA, Wadl H, Eichler HG, Wolff K, van Elsas A, Schrier PI and Pehamberger H: N-ras oncogene expression changes the growth characteristics of human melanoma in two independent SCID-hu mouse models. Int J Cancer 67: 821-825, 1996.
10. Jansen B, Schlagbauer-Wadl H, Eichler HG, Wolff K, van Elsas A, Schrier PI and Pehamberger H: Activated N-ras contributes to the chemoresistance of human melanoma in severe combined immunodeficiency (SCID) mice by blocking apoptosis. Cancer Res 57: 362-365, 1997.
11. Grossman D and Altieri DC: Drug resistance in melanoma: Mechanisms, apoptosis, and new potential therapeutic targets. Cancer Metastasis Rev 20: 1-2, 2001.
12. Vucic D, Stennicke HR, Pisabarro MT, Salvesen GS and Dixit VM: ML-IAP, a novel inhibitor of apoptosis that is preferentially expressed in human melanomas. Curr Biol 10: 1359-1366, 2000.
13. Kaufmann WK: Pathways of human cell post-replication repair. Carcinogenesis 10: 1-11, 1989.
14. Hannun YA: Apoptosis and the dilemma of cancer chemotherapy. Blood 89: 1845-1853, 1997.
15. Gewirtz DA: A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 57: 727-741, 1999.
16. Drukala J, Rajwa B and Pietrzkowski Z: Effect of daunomycin on expression of CD44H protein in HTB140 melanoma cells in vitro. Anticancer Res 21: 3793-3798, 2001.
17. Laurent G and Jaffrezou JP: Signaling pathways activated by daunorubicin. Blood 98: 913-924, 2001.
18. Dunn GA and Brown AF: Alignment of fibroblasts on grooved surfaces described by a simple geometric transformation. J Cell Sci 83: 313-340, 1986.
19. Gorczyca W, Tuziak T, Kram A, Melamed M and Darzynkiewicz Z: Detection of apoptosis-associated DNA strand breaks in fine-needle aspiration biopsies by in-situ end labeling of fragmented DNA. Cytometry 15: 169-175, 1994.
20. Madeja Z, Kupiec M and Korohoda W: Morphometric analysis of LPS-stimulated human monocytes by computer-assisted image analysis. Folia Biol (Krakow) 46: 123-128, 1998.
21. Borenfreund E, Babich H and Martin-Alguacil N: Rapid assay with human normal and tumor cells in vitro. In Vitro Cell Dev Biol Anim 26: 1030-1034, 1990.
22. Williams GT: Programmed cell death: apoptosis and oncogenesis. Cell 65: 1097-1098, 1991.
23. Kerr JF, Winterford CM and Harmon BV: Apoptosis. Its significance in cancer and cancer therapy. Cancer 73: 2013-2026, 1994.
24. Mooney EE, Ruis Peris JM, ONeill A and Sweeney EC: Apoptotic and mitotic indices in malignant melanoma and basal cell carcinoma. J Clin Pathol 48: 242-244, 1995.
25. Staunton MJ and Gaffney EF: Tumor type is a determinant of susceptibility to apoptosis. Am J Clin Pathol 103: 300-307, 1995.
26. Glinsky GV, Glinsky W, Ivanova AB and Hueser CJ: Apoptosis and metastasis: increased apoptosis resistance of metastatic cancer cells is associated with the profound deficiency of apoptosis execution mechanisms. Cancer Lett 115: 185-193, 1997.
27. Alanko T, Rosenberg M and Saksela O: FGF expression allows nevus cells to survive in three-dimensional collagen gel under conditions that induce apoptosis in normal human melanocytes. J Invest Dermat 113: 111-116, 1999.
28. Shapiro GI, Edwards CD, Ewen ME and Rollins BJ: p16INK4A participates in a G1 arrest checkpoint in response to DNA damage. Mol Cell Biol 18: 378-387, 1998.
29. Fornari FA, Jarvis WD, Grant S, Orr MS, Randolph JK, White FKH and Gewirtz DA: Growth arrest and non-apoptotic cell death associated with the suppression of c-myc expression in MCF-7 breast tumor cells following acute exposure to doxorubicin. Biochem Pharmacol 51: 931-940, 1996.
30. Ling YH, El-Naggar AK, Priebe W and Perez-Soler R: Cell cycle-dependent cytotoxicity, G2/M phase arrest, and disruption of p34(cdc2)/cyclin B-1 activity induced by doxorubicin in synchronized P388 cells. Mol Pharmacol 49: 832-841, 1996.
31. Colombo R, Necco A, Vailati G and Milzani A: Dose-dependence of doxorubicin effect on actin assembly in vitro. Exp Mol Pathol 49: 297-304, 1988.
32. Colombo R and Milzani A: How does doxorubicin interfere with actin polymerization? Biochim Biophys Acta 968: 9-16, 1988.
33. Molinari A, Calcabrini A, Crated P and Arancia G: Interaction of anthracyclinic antibiotics with cytoskeletal components of cultured carcinoma cells (CG5). Exp Mol Pathol 53: 11-33, 1990.
34. Ling YH, Priebe W and Perez-Soler R: Apoptosis induced by anthracycline antibiotics in P388 parent and multidrug-resistant cells. Cancer Res 53: 1845-1852, 1993.
35. Skladanowski A and Konopa J: Adriamycin and daunomycin induce programmed cell death (apoptosis) in tumour cells. Biochem Pharmacol 46: 375-382, 1993.
36. Jaffrezou JP, Levade T, Bettaieb A, Andrieu N, Bezombes C, Maestre N, Vermeersch S, Rousse A and Laurent G: Daunorubicin-induced apoptosis: triggering of ceramide generation through sphingomyelin hydrolysis. EMBO J 15: 2417-2424, 1996.
37. Grandi M, Pezzoni G, Ballinari D, Capolongo L, Suarato A, Bargiotti A, Faiardi D and Spreafico F: Novel anthracycline analogs. Cancer Treat Rev 17: 133-138, 1990.
38. Henseleit U, Rosenbach T and Kolde G: Induction of apoptosis in human HaCaT keratinocytes. Arch Dermatol Res 288: 676-683, 1996.
39. Lee MM, Ratliff J, FitzGerald GB and Wick MM: The mechanism of differential sensitivity to methotrexate of normal and malignant human epidermal cells. Cancer Chemothe Pharmacol 28: 181-184, 1991.